North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence ...

New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

Aflibercept (Eylea) 2 mg prefilled syringes and 2 mg vials had the highest incidence of IOP spikes ≥10 mm Hg among all ...

Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, and placental growth factor.

In both trials, patients treated with aflibercept 8 mg (PULSAR n=673; PHOTON n=491) met the primary endpoint of non-inferiority in vision gains for both the 12- and 16-week dosing regimens after ...

Biosimilar aflibercept (P041) exhibited similar effectiveness and safety as originator aflibercept (Eylea) in retinal conditions like neovascular age-related macular degeneration (nAMD), according ...

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.

Vabysmo reduced retinal fluid from baseline compared to aflibercept, as measured by reduction in central subfield thickness (CST). At 12 weeks, CST reductions were 145 µm in the Vabysmo arm and ...

Intravitreal injections of aflibercept every 4 weeks after monthly injections may provide an additional benefit to patients with early persistent fluid from neovascular age-related macular ...

Aflibercept 8 mg is investigational, and its safety and efficacy have not been fully evaluated by any regulatory authority. Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG.